Ultra-high dose radiation for Liver metastasis using MR-guided TReatment with stereotactic Ablative Single-fraction (ULTRAS): study protocol for a phase III randomized controlled trial
Contemporary Clinical Trials · 2026-08 · 167 · 108381
DOI: 10.1016/j.cct.2026.108381 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Contemporary Clinical Trials, 2026-08. Verfasst von Harroun Wong und 17 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. Hauptthemen laut MEDLINE: Liver Neoplasms, Radiosurgery, Radiotherapy, Image-Guided. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Elekta AB.
Abstract (Originalsprache)
INTRODUCTION Liver metastases are common in several malignancies, with only 15-20% of patients eligible for surgical resection. For non-surgical candidates, stereotactic body radiation therapy (SBRT) is an effective alternative with acceptable local control (LC) rates. Higher biologically effective doses (BED10 > 100 Gy10) are associated with improved LC, and single-fraction ultra-high dose SBRT (35-40 Gy) has demonstrated excellent LC with minimal toxicity. MR-guided adaptive SBRT enhances precision and may optimizing single-fraction SBRT for liver metastases. METHODS AND ANALYSIS ULTRAS is a multi-center, phase III randomized trial evaluating whether ultra-high dose MR-guided single-fraction SBRT (38 Gy, BED10 ≈ 180 Gy10) improves LC of liver oligometastases/oligoprogression compared to high-dose MR-guided single-fraction SBRT (27 Gy, BED10 ≈ 100 Gy10). Primary endpoint is LC of treated intrahepatic target lesion(s). Secondary endpoints include overall survival (OS), progression-free survival (PFS), intrahepatic and extrahepatic progression, toxicity (CTCAE v5.0 and PRO-CTCAE v1.0), and quality of life (QOL) (EORTC QLQ-C15-PAL, EORTC QLQ-LM21). Patients will be randomized 1:1 to receive either 27 Gy or 38 Gy, stratified by primary tumor site/histology, lesion characteristics, and prior systemic therapy. A total of 114 patients (57 per arm) will be enrolled over three years, with two years of follow-up. Assessments at predefined intervals will monitor response and toxicity. LC will be analyzed using cumulative incidence function. Widespread and intrahepatic progression will be assessed using Fine & Gray regression; OS and PFS via Cox models; toxicity and QOL via Chi-squared test and mixed-effects model. ETHICS AND DISSEMINATION The ULTRAS trial obtained ethical approval from the University Health Network and will follow ICMJE reporting standards. TRIAL REGISTRATION ClinicalTrials.gov ID: NCT06362395.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
- Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan.
- Department of Radiation Oncology, Tom Baker Cancer Centre, Calgary, Canada.
- Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. Electronic address: zhihuiamy.liu@uhn.ca.
- St. Vincent's GenesisCare, Darlinghurst, New South Wales, Australia.
Förderung
- Elekta AB
Zitieren
APA
Wong, H., Ng, S. S. W., Mohamad, I., Alborz, J., Stanescu, T., Liu, Z. A., De Leon, J., Tan, H., Ng, S. P., Radhakrishna, G., Bahij, R., Intven, M., Kirichenko, A., Mesci, A., Yan, M., Dawson, L., Augilera, T., & Hosni, A. (2026). Ultra-high dose radiation for Liver metastasis using MR-guided TReatment with stereotactic Ablative Single-fraction (ULTRAS): study protocol for a phase III randomized controlled trial. Contemporary Clinical Trials, 167, 108381. https://doi.org/10.1016/j.cct.2026.108381
Vancouver
Wong H, Ng SSW, Mohamad I, Alborz J, Stanescu T, Liu ZA, et al. Ultra-high dose radiation for Liver metastasis using MR-guided TReatment with stereotactic Ablative Single-fraction (ULTRAS): study protocol for a phase III randomized controlled trial. Contemporary Clinical Trials. 2026;167:108381. doi:10.1016/j.cct.2026.108381
BibTeX
@article{Wong2026,
author = {Wong, Harroun and Ng, Sylvia S W and Mohamad, Issa and Alborz, Jooya and Stanescu, Teodor and Liu, Zhihui Amy and De Leon, Jeremy and Tan, Hendrick and Ng, Sweet Ping and Radhakrishna, Ganesh and Bahij, Rana and Intven, Martijn and Kirichenko, Alexander and Mesci, Aruz and Yan, Michael and Dawson, Laura and Augilera, Todd and Hosni, Ali},
title = {Ultra-high dose radiation for Liver metastasis using MR-guided TReatment with stereotactic Ablative Single-fraction (ULTRAS): study protocol for a phase III randomized controlled trial},
journal = {Contemporary Clinical Trials},
year = {2026},
volume = {167},
pages = {108381},
doi = {10.1016/j.cct.2026.108381}
}
EUVIMED